NanoViricides (NNVC) Peer Comparison

$1.12

$-0.52 (-31.71%)

As on 04-Sep-2026 16:18EDT

Market cap

$29 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

3.4

Div. Yield

0 %

Edit

	NanoViricides (NNVC)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)	29	16,504	17,747	14,622	12,501
Revenue ($ Mln)	--	2,782	1,054	2,436	1,284
Net Profit ($ Mln)	-8.09	491.50	755.85	860.62	-325.10
Net Margin (%)	--	17.67	71.69	35.33	-25.32
RoE (%)	-99.10	110.09	--	42.98	-57.72
Price to Earnings	--	34.72	20.93	18.56	--
Price-To-Book	3.37	38.18	10.51	7.95	23.94

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	NanoViricides (NNVC)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Operating Revenue	0.00	2,782.29	1,054.37	2,435.92	1,283.94
Cost of Revenue	0.56	1,982.07	103.47	85.67	109.42
Gross Profit	-0.74	760.62	588.53	2,236.43	902.26
Operating Expenses	8.05	216.81	841.45	1,378.74	1,497.13
Operating Profit (EBIT)	-8.18	583.40	109.45	971.51	-322.62
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-8.09	598.92	101.11	1,035.47	-325.10
Provision for Tax	0.00	107.42	-654.74	174.84	0.00
Profit after Tax (Net Income)	-8.09	491.50	755.85	860.62	-325.10
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	NanoViricides (NNVC)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Shareholder's Funds	9.15	433.86	1,435.90	1,843.76	523.72
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	0.00	187.89	384.48	288.55	346.72
Current Liabilities	1.07	1,435.43	464.70	361.93	374.20
Total Liabilities	8.82	1,975.47	1,302.02	2,844.42	1,259.59

Assets ($ Mln)

	NanoViricides (NNVC)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Non-Current Assets	6.84	1,006.90	895.24	1,243.41	45.47
Current Assets	3.38	1,050.29	1,389.84	1,250.82	1,199.18
Total Assets	8.82	1,975.47	1,302.02	2,844.42	1,259.59
Total Debt*	0.00	120.10	449.89	165.93	347.75
Net Current Assets	2.31	-385.14	925.52	888.90	824.98

Cashflow ($ Mln)

	NanoViricides (NNVC)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Cash From Operating Activities	-8.48	713.22	51.77	884.27	-189.55
Cash Flow from Investing Activities	-0.06	-31.14	-8.15	350.44	32.32
Cash from Financing Activities	5.30	-860.39	34.89	-969.59	255.98
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	NanoViricides (NNVC)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
ROCE (%)	-99.75	53.56	-30.01	32.82	-31.49
ROE (%)	-99.10	110.09	163.18	42.98	-57.72
ROA (%)	-71.87	15.64	31.68	29.32	-22.97
EBIT Margin (%)	--	21.13	5.73	31.04	-18.97
Net Margin (%)	--	17.67	71.69	35.33	-25.32
Cash Profit Margin (%)	--	0.00	0.00	0.00	0.00

Growth Ratios

	NanoViricides (NNVC)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Revenue Growth (%)	--	24.67	114.85	9.23	149.04
EBIT Growth (%)	16.82	18.70	136.39	-3.99	9.16
Net Profit Growth (%)	16.82	17.50	378.76	42.89	-15.32
EPS Growth (%)	38.15	26.84	353.27	50.42	-0.64
Book Value Growth (%)	-23.14	164.02	816.12	-0.70	-42.66

Valuation Ratios

	NanoViricides (NNVC)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Price / Earnings	-2.44	36.06	-59.76	15.79	-45.32
Price / Book Value	3.37	38.18	10.51	7.95	23.94
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00
EV/EBITDA	-3.69	27.00	230.43	13.21	-39.74
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	NanoViricides (NNVC)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debt to Equity	0.00	0.00	0.27	0.00	0.65
Short term debt to equity ratio	0.00	0.00	0.05	0.00	0.00
Current Ratio	3.17	0.73	2.99	3.46	3.20
Quick Ratio	3.17	0.73	2.32	3.38	2.94
Interest Coverage	-0.06	--	1.62	--	-9.32

Operating Efficiency Ratios

	NanoViricides (NNVC)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debtors to sales (%)	--	15.88	21.25	13.74	14.98
Asset Turnover	0.00	0.89	0.44	0.83	0.91
Receivable days	--	50.42	85.52	43.48	35.88
Inventory Days	--	--	1,056.70	96.17	354.23
Payable days	205.11	6.26	331.01	147.97	300.79
Cash Conversion Cycle	--	--	811.21	-8.32	89.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly